proxyvotesnow.com

Home › Companies › Madrigal Pharmaceuticals, Inc. › 2024-2025

Madrigal Pharmaceuticals, Inc. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and Madrigal Pharmaceuticals, Inc.’s Form 8-K, filed June 20, 2025 (Item 5.07 on EDGAR). Page generated October 18, 2026.

  • 7Reported items
  • 332Asset managers
  • 2,758Fund votes
  • June 20, 2025Meeting date

Results at a glance

Meeting of June 20, 2025: 6 items on Madrigal Pharmaceuticals, Inc.’s Form 8-K, filed June 20, 2025: 4 elected · 2 approved.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Madrigal Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Madrigal Pharmaceuticals, Inc.

These tallies are Madrigal Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 20, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Madrigal Pharmaceuticals, Inc. — official shareholder meeting results, meeting held June 20, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Julian C. Baker 17,144,833---- 1,806,0701,476,517 90%Elected—
Elect Director: Raymond Cheong, Ph.D., M.D. 18,218,687---- 732,2161,476,517 96%Elected—
Elect Director: Jacqualyn A. Fouse, Ph.D. 18,845,616---- 105,2871,476,517 99.4%Elected—
Elect Director: Richard S. Levy, M.D. 17,734,255---- 1,216,6481,476,517 94%Elected—
2. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 20,230,193179,95917,269 --0 99.1%Approved—
3. On a non-binding, advisory basis, the compensation of the Company's named executive officers 18,720,175208,91121,817 --1,476,517 99%Approved—

Source: Madrigal Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 20, 2025 — read the filing on EDGAR.

How asset managers voted at the Madrigal Pharmaceuticals, Inc. 2024-2025 meeting

Each item below shows how the 332 asset managers that disclosed a Madrigal Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Madrigal Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Jacqualyn A. Fouse, Ph.D.

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 18,845,616WITHHELD: 105,287
Details: description as filed, official tally, votes by 82 asset managers

Description as filed by funds: Re-election of Class III directors: Jacqualyn Fouse, Ph.D.

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jacqualyn A. Fouse, Ph.D.”): 18,845,616 for, 105,287 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class III directors, each to serve until the Company's 2028 annual meeting of stockholders or until his or her successor is duly elected and qualified.”
Support: 99.4% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 79 asset managers voting on “Re-election of Class III directors: Jacqualyn Fouse, Ph.D.” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard1,780,7230 0151For
JANUS INVESTMENT FUND1,404,1910 00For
Fidelity421,3960 00For
T. Rowe Price369,8820 00For
State Street360,4140 00For
BlackRock330,9400 00For
Charles Schwab153,7930 00For
Artisan93,9230 00For
WILLIAM BLAIR FUNDS73,1880 00For
Lord Abbett64,7270 00For
Federated Hermes58,0250 00For
Goldman Sachs54,4140 00For
Jackson National51,0290 00For
Equitable50,3360 00For
TIAA44,7380 00For
AIG/SunAmerica44,7190 00For
Victory Capital44,6000 00For
Invesco42,4920 00For
Bridge Builder Trust36,7930 00For
Brighthouse33,6430 01,407For
JANUS ASPEN SERIES33,9460 00For
American Century29,8740 00For
Lincoln Financial23,5000 00For
MERIDIAN FUND INC23,4770 00For
Putnam22,8700 00For

Fund voting reports, all 79 managers: 5,914,839 for, 32,961 withheld, 6,057 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 3 asset managers voting on “Re-election of Class III directors: Jacqualyn Fouse, Ph.D.” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH164,4000 00For
BRANDYWINE OAK PRIVATE WEALTH LLC320 00For
MARCO INVESTMENT MANAGEMENT LLC10 00For

Institutional-manager reports, all 3 managers: 164,433 for.

2. Elect Director: Julian C. Baker

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 17,144,833WITHHELD: 1,806,070
Details: description as filed, official tally, votes by 82 asset managers

Description as filed by funds: Re-election of Class III directors: Julian Baker

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Julian C. Baker”): 17,144,833 for, 1,806,070 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class III directors, each to serve until the Company's 2028 annual meeting of stockholders or until his or her successor is duly elected and qualified.”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 79 asset managers voting on “Re-election of Class III directors: Julian Baker” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard1,780,7230 0151For
JANUS INVESTMENT FUND1,404,1910 00For
Fidelity421,3960 00For
T. Rowe Price00 0369,882Withhold
State Street1,5390 0358,875Withhold
BlackRock330,9400 00For
Charles Schwab153,7930 00For
Artisan93,9230 00For
WILLIAM BLAIR FUNDS73,1880 00For
Lord Abbett64,7270 00For
Federated Hermes00 058,025Withhold
Goldman Sachs54,4140 00For
Jackson National12,7620 038,267Mixed
Equitable27,6120 022,724Mixed
TIAA44,7380 00For
AIG/SunAmerica44,7190 00For
Victory Capital44,6000 00For
Invesco00 042,492Withhold
Bridge Builder Trust27,8900 08,903Mixed
Brighthouse6,4950 028,555Mixed
JANUS ASPEN SERIES33,9460 00For
American Century29,8740 00For
Lincoln Financial4,1010 019,399Mixed
MERIDIAN FUND INC23,4770 00For
Putnam22,8700 00For

Fund voting reports, all 79 managers: 4,913,964 for, 1,033,836 withheld, 6,057 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 3 asset managers voting on “Re-election of Class III directors: Julian Baker” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH164,4000 00For
BRANDYWINE OAK PRIVATE WEALTH LLC320 00For
MARCO INVESTMENT MANAGEMENT LLC10 00For

Institutional-manager reports, all 3 managers: 164,433 for.

3. Elect Director: Raymond Cheong, Ph.D., M.D.

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 18,218,687WITHHELD: 732,216
Details: description as filed, official tally, votes by 82 asset managers

Description as filed by funds: Re-election of Class III directors: Raymond Cheong, M.D., Ph.D.

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Raymond Cheong, Ph.D., M.D.”): 18,218,687 for, 732,216 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class III directors, each to serve until the Company's 2028 annual meeting of stockholders or until his or her successor is duly elected and qualified.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 79 asset managers voting on “Re-election of Class III directors: Raymond Cheong, M.D., Ph.D.” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard1,780,7230 0151For
JANUS INVESTMENT FUND1,404,1910 00For
Fidelity421,3960 00For
T. Rowe Price00 0369,882Withhold
State Street360,4140 00For
BlackRock330,9400 00For
Charles Schwab153,7930 00For
Artisan93,9230 00For
WILLIAM BLAIR FUNDS73,1880 00For
Lord Abbett64,7270 00For
Federated Hermes58,0250 00For
Goldman Sachs54,4140 00For
Jackson National51,0290 00For
Equitable27,6120 022,724Mixed
TIAA44,7380 00For
AIG/SunAmerica44,7190 00For
Victory Capital44,6000 00For
Invesco42,4920 00For
Bridge Builder Trust27,8900 08,903Mixed
Brighthouse25,7150 09,335Mixed
JANUS ASPEN SERIES33,9460 00For
American Century29,8740 00For
Lincoln Financial17,3750 06,125Mixed
MERIDIAN FUND INC23,4770 00For
Putnam22,8700 00For

Fund voting reports, all 79 managers: 5,483,583 for, 464,217 withheld, 6,057 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 3 asset managers voting on “Re-election of Class III directors: Raymond Cheong, M.D., Ph.D.” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH164,4000 00For
BRANDYWINE OAK PRIVATE WEALTH LLC320 00For
MARCO INVESTMENT MANAGEMENT LLC10 00For

Institutional-manager reports, all 3 managers: 164,433 for.

4. Elect Director: Richard S. Levy, M.D.

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 17,734,255WITHHELD: 1,216,648
Details: description as filed, official tally, votes by 82 asset managers

Description as filed by funds: Re-election of Class III directors: Richard Levy, M.D.

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Richard S. Levy, M.D.”): 17,734,255 for, 1,216,648 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The Company's stockholders re-elected the four persons listed below as Class III directors, each to serve until the Company's 2028 annual meeting of stockholders or until his or her successor is duly elected and qualified.”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 79 asset managers voting on “Re-election of Class III directors: Richard Levy, M.D.” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard1,780,7230 0151For
JANUS INVESTMENT FUND1,404,1910 00For
Fidelity421,3960 00For
T. Rowe Price00 0369,882Withhold
State Street360,4140 00For
BlackRock330,9400 00For
Charles Schwab153,7930 00For
Artisan93,9230 00For
WILLIAM BLAIR FUNDS73,1880 00For
Lord Abbett64,7270 00For
Federated Hermes58,0250 00For
Goldman Sachs54,4140 00For
Jackson National51,0290 00For
Equitable27,6120 022,724Mixed
TIAA44,7380 00For
AIG/SunAmerica44,7190 00For
Victory Capital44,6000 00For
Invesco42,4920 00For
Bridge Builder Trust27,8900 08,903Mixed
Brighthouse25,7150 09,335Mixed
JANUS ASPEN SERIES33,9460 00For
American Century29,8740 00For
Lincoln Financial17,3750 06,125Mixed
MERIDIAN FUND INC23,4770 00For
Putnam22,8700 00For

Fund voting reports, all 79 managers: 5,483,583 for, 464,217 withheld, 6,057 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 3 asset managers voting on “Re-election of Class III directors: Richard Levy, M.D.” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH164,4000 00For
BRANDYWINE OAK PRIVATE WEALTH LLC320 00For
MARCO INVESTMENT MANAGEMENT LLC10 00For

Institutional-manager reports, all 3 managers: 164,433 for.

5. 3. On a non-binding, advisory basis, the compensation of the Company's named executive officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

99% Approved · of votes cast

FOR 99%
FOR: 18,720,175AGAINST: 208,911
Details: description as filed, official tally, votes by 332 asset managers

Description as filed by funds: Advisory vote to approve executive compensation

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“3. On a non-binding, advisory basis, the compensation of the Company's named executive officers”): 18,720,175 for, 208,911 against — passed, per its Form 8-K filed June 20, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 80 asset managers voting on “Advisory vote to approve executive compensation” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard1,780,723151 00For
JANUS INVESTMENT FUND1,404,1910 00For
Fidelity421,3960 00For
T. Rowe Price369,8820 00For
State Street360,4140 00For
BlackRock330,9400 00For
Charles Schwab153,7930 00For
Artisan93,9230 00For
WILLIAM BLAIR FUNDS73,1880 00For
Lord Abbett64,7270 00For
Federated Hermes58,0250 00For
Goldman Sachs54,4140 00For
Jackson National51,0290 00For
Equitable50,3360 00For
TIAA44,7380 00For
AIG/SunAmerica44,7190 00For
Victory Capital44,6000 00For
Invesco42,4920 00For
Bridge Builder Trust36,7930 00For
Brighthouse33,6430 1,4070For
JANUS ASPEN SERIES33,9460 00For
American Century29,8740 00For
Lincoln Financial23,5000 00For
MERIDIAN FUND INC23,4770 00For
Putnam22,8700 00For

Fund voting reports, all 80 managers: 5,957,180 for, 1,572 against, 1,407 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 273 asset managers voting on “Advisory vote to approve executive compensation” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RTW INVESTMENTS, LP1,993,6870 00For
BAKER BROS. ADVISORS LP1,974,5900 00For
Janus Henderson1,877,9930 00For
State Street673,3280 00For
T. Rowe Price505,3600 00For
BlackRock466,8110 00For
GEODE CAPITAL MANAGEMENT, LLC390,7230 00For
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC283,9220 00For
Woodline Partners LP272,3680 00For
Avoro Capital Advisors LLC205,4460 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.198,3910 00For
PICTET ASSET MANAGEMENT SA188,4740 00For
Rock Springs Capital Management LP166,6980 00For
Erste Asset Management GmbH164,4000 00For
Charles Schwab154,0390 00For
Fidelity152,3990 00For
ArrowMark Colorado Holdings LLC151,4610 00For
Fiera Capital Corp121,9360 00For
ARMISTICE CAPITAL, LLC111,0440 00For
Artisan99,9190 00For
Hood River Capital Management LLC96,4120 00For
Northern Trust78,3740 00For
Victory Capital78,2730 00For
LORD, ABBETT & CO. LLC75,1890 00For
EcoR1 Capital, LLC75,0000 00For

Institutional-manager reports, all 273 managers: 11,766,833 for, 105,840 against, 3,436 abstained, 28 not voted, 6,694 1 year. Showing the 25 largest; see all in the interactive database.

6. Advisory vote to approve the frequency of future advisory votes to approve executive compensation

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

99.9% Fund and manager reports combined; may count the same shares twice · no official result

1 YEAR
Details: votes by 312 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 77 asset managers voting on “Advisory vote to approve the frequency of future advisory votes to approve executive compensation” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard00 00--
JANUS INVESTMENT FUND00 00--
Fidelity00 00--
T. Rowe Price00 00--
State Street00 00--
BlackRock00 00--
Charles Schwab00 00--
Artisan00 00--
WILLIAM BLAIR FUNDS00 00--
Lord Abbett00 00--
Federated Hermes00 00--
Goldman Sachs00 00--
Jackson National00 00--
Equitable00 00--
TIAA00 00--
AIG/SunAmerica00 00--
Victory Capital00 00--
Invesco00 00--
Bridge Builder Trust00 00--
JANUS ASPEN SERIES00 00--
American Century00 00--
Lincoln Financial4,1010 00For
MERIDIAN FUND INC00 00--
Putnam00 00--
New York Life00 00--

Fund voting reports, all 77 managers: 4,101 for, 1,407 abstained, 5,918,715 1 year, 5,521 3 year, 3,698 2 year, 0 unknown. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 256 asset managers voting on “Advisory vote to approve the frequency of future advisory votes to approve executive compensation” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RTW INVESTMENTS, LP00 00--
BAKER BROS. ADVISORS LP00 00--
Janus Henderson00 00--
State Street00 00--
T. Rowe Price00 00--
BlackRock00 00--
GEODE CAPITAL MANAGEMENT, LLC00 00--
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC00 00--
Woodline Partners LP00 00--
Avoro Capital Advisors LLC00 00--
PICTET ASSET MANAGEMENT SA00 00--
Rock Springs Capital Management LP00 00--
Charles Schwab00 00--
Fidelity00 00--
ArrowMark Colorado Holdings LLC00 00--
ARMISTICE CAPITAL, LLC00 00--
Artisan00 00--
Hood River Capital Management LLC96,4120 00For
Northern Trust00 00--
Victory Capital00 00--
LORD, ABBETT & CO. LLC00 00--
EcoR1 Capital, LLC00 00--
Holocene Advisors, LP00 00--
Federated Hermes00 00--
Invesco00 00--

Institutional-manager reports, all 256 managers: 106,447 for, 108 against, 28 not voted, 11,177,746 1 year, 52,172 3 year. Showing the 25 largest; see all in the interactive database.

7. 2. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

99.1% Approved · of votes cast

FOR 99.1%
FOR: 20,230,193AGAINST: 179,959
Details: description as filed, official tally, votes by 81 asset managers

Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025

Madrigal Pharmaceuticals, Inc.’s own tally for this item (“2. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 20,230,193 for, 179,959 against — passed, per its Form 8-K filed June 20, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 81 asset managers below reported 5,914,604 for, 23,961 against, 1,407 abstained.

FOR
FOR: 5,914,604AGAINST: 23,961ABSTAIN: 1,407
Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public account” at Madrigal Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard1,780,8740 00For
JANUS INVESTMENT FUND1,404,1910 00For
Fidelity421,3960 00For
T. Rowe Price369,8820 00For
State Street360,290124 00For
BlackRock330,9400 00For
Charles Schwab153,7930 00For
Artisan93,9230 00For
WILLIAM BLAIR FUNDS73,1880 00For
Lord Abbett64,7270 00For
Federated Hermes58,0250 00For
Goldman Sachs54,4140 00For
Jackson National51,0290 00For
Equitable50,3360 00For
TIAA44,7380 00For
AIG/SunAmerica44,7190 00For
Victory Capital44,6000 00For
Invesco42,4920 00For
Bridge Builder Trust27,8908,903 00Mixed
JANUS ASPEN SERIES33,9460 00For
American Century29,8740 00For
Lincoln Financial23,5000 00For
MERIDIAN FUND INC23,4770 00For
Putnam22,8700 00For
New York Life17,9871,673 00Mixed

Showing the 25 largest of 81 asset managers. See all 81 in the interactive database.

Largest Madrigal Pharmaceuticals, Inc. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 22,187,716 shares outstanding at the time of that meeting.

Fund voting reports: top Madrigal Pharmaceuticals, Inc. shareholders by shares voted on “Advisory vote to approve executive compensation”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 8.03%
2JANUS INVESTMENT FUND 6.33%
3Fidelity 1.90%
4T. Rowe Price 1.67%
5State Street 1.62%
6BlackRock 1.49%
7Charles Schwab 0.69%
8Artisan 0.42%
9WILLIAM BLAIR FUNDS 0.33%
10Lord Abbett 0.29%
Institutional-manager reports: top Madrigal Pharmaceuticals, Inc. shareholders by shares voted on “Advisory vote to approve executive compensation”, 2024-2025
#Asset manager % of shares outstanding
1RTW INVESTMENTS, LP 8.99%
2BAKER BROS. ADVISORS LP 8.90%
3Janus Henderson 8.46%
4State Street 3.03%
5T. Rowe Price 2.28%
6BlackRock 2.10%
7GEODE CAPITAL MANAGEMENT, LLC 1.76%
8WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 1.28%
9Woodline Partners LP 1.23%
10Avoro Capital Advisors LLC 0.93%

Reported Madrigal Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Madrigal Pharmaceuticals, Inc. holdings and ownership disclosed for the 2024-2025 proxy season
Holder % outstanding Disclosure
Julian C. Baker 10.11% DEF14A
Paul Friedman, M.D. 9.53% DEF14A
JANUS HENDERSON GROUP PLC 9.10% 13G
Paul A Friedman, M.D. 8.18% 13D
Rebecca Taub, M.D. 8.18% 13D
Vanguard Group 7.62% 13F
BlackRock 6.70% 13F
PAULSON & CO. INC. 6.27% 13G
State Street 3.42% 13F
FMR (Fidelity) 2.94% 13F

Percentages above are of 22,187,716 shares outstanding, as reported by Madrigal Pharmaceuticals, Inc. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Madrigal Pharmaceuticals, Inc.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At Madrigal Pharmaceuticals, Inc.'s shareholder meeting held June 20, 2025, in the 2024-2025 proxy season, 332 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,758 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Advisory vote to approve executive compensation — Madrigal Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 99% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Madrigal Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 20, 2025.

Madrigal Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.